Commitment to equal access to the Janssen COVID-19 vaccine worldwide

Global equity has been at the forefront of the Johnson & Johnson COVID-19 response from the beginning of the pandemic – from implementing a global clinical development plan which studied the vaccine in diverse populations in Africa, Latin America, the U.S. and Europe, through to a commitment to make available up to 900 million vaccine doses to the African Union and COVAX Facility, combined, through 2022. We are committed to providing our COVID-19 vaccine globally on a not-for-profit basis for emergency pandemic use.

In 2021, through our supply agreements and country donations, approximately 70% of the Johnson & Johnson COVID-19 vaccine supply was made available to low and middle-income countries.[1] In 2022, Johnson & Johnson will continue to focus significant efforts on vaccine deliveries to low and middle- income countries as we deliver on our supply agreements with COVAX, the African Union and other countries.

To help meet the global need for COVID-19 vaccines, we have forged new manufacturing partnerships across four continents, including with Biological E. in India and Aspen Pharmacare in South Africa. We continue to work to expand our manufacturing network and are confident that once Biological E. is fully integrated it will be an important part of our global COVID-19 vaccine supply chain network.

Additionally, we have reached an advanced stage in discussions for a potential licensing agreement for our COVID-19 vaccine with Aspen Pharmacare in South Africa. If finalized, this agreement would enable the first COVID-19 vaccine to be manufactured and sold by an African company for people living in Africa.

Johnson & Johnson firmly believes that inequitable access to COVID-19 vaccines will only prolong the pandemic. We’re proud to be working with governments, WHO, Gavi, UNICEF and PAHO to ensure that the donated vaccines are delivered to recipient countries as quickly as possible.